To develop a widely accessible, inexpensive point-of-care diagnostic kit requires an accountable leadership, decisive science-based governance, significant financing, and the application of reliable principle-based scientific protocols to determine whom to test, how to interpret results, and how best to treat and quarantine those infected. Taking these actions now cannot only greatly help contain the current Covid-19 epidemic; it can also create a system for developing similar tools to stop future pandemics.
Related topics
Topic | Replies | Views | Activity | |
---|---|---|---|---|
We Need a Cheap Way to Diagnose Coronavirus | 0 | 345 | February 29, 2020 | |
The Unknown Unknowns: Diagnosing the New Coronavirus | 0 | 275 | March 11, 2020 | |
Covid-19 Testing Is Expensive. It Doesn't Have to Be | 0 | 363 | June 1, 2020 | |
Coronavirus (COVID-19) Update: FDA Issues New Policy to Help Expedite Availability of Diagnostics | 0 | 307 | March 16, 2020 | |
Advice on the use of point-of-care immunodiagnostic tests for COVID-19 | 0 | 573 | April 14, 2020 |